Home Cart Sign in  
Chemical Structure| 1448867-41-1 Chemical Structure| 1448867-41-1
Chemical Structure| 1448867-41-1
Product Citations

Alternative Products

Product Details of Siremadlin

CAS No. :1448867-41-1
Formula : C26H24Cl2N6O4
M.W : 555.41
SMILES Code : O=C1N(C2=CC(Cl)=CN(C)C2=O)[C@@H](C3=CC=C(Cl)C=C3)C4=C1N=C(C5=CN=C(OC)N=C5OC)N4C(C)C
Synonyms :
HDM201; NVP-HDM 201; NVP-HDM201
MDL No. :MFCD30502893
InChI Key :AGBSXNCBIWWLHD-FQEVSTJZSA-N
Pubchem ID :71678098

Safety of Siremadlin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
A375 cells 62.5 nmol/L to 4000 nmol/L 28-80 hours PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of A375 cells and reduced S-phase entry. PMC9656205
A375 cells 12.5 nmol/L to 200 nmol/L 72 hours PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of A375 cells and reduced S-phase entry. PMC9656205
SK-Hep-1 cells 0-10 µM 72 and 96 hours Evaluate the effect of HDM201 alone or in combination with GSK2830371 on cell proliferation. GSK2830371 significantly enhanced the growth inhibitory and cytotoxic activity of HDM201. PMC8345393
RBE cells 0-10 µM 72 and 96 hours To evaluate the antitumor effect of Ro3280 on cholangiocarcinoma cells, results showed that Ro3280 significantly inhibited cell proliferation and induced apoptosis. PMC8345393

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
CD-1 nude mice A375 melanoma tumor model Oral 40 mg/kg or 100 mg/kg Siremadlin: qdx3 (every 3 days); Trametinib: qdx6 (every 6 days) To evaluate the antitumor effects of Siremadlin and Trametinib alone and in combination in an A375 melanoma tumor model. Results showed significantly higher tumor growth inhibition when used in combination compared to monotherapy. PMC9656205
CD-1 nude mice A375 xenograft model Oral 40/100 mg/kg Every 3 days To evaluate the antitumor efficacy of siremadlin in A375 xenograft model PMC9570053

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05599932 Hepatic Impairment PHASE1 COMPLETED 2023-09-18 Clinical Pharmacology of Miami... More >> LLC, Miami, Florida, 33014-3616, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|Texas Liver Institute, San Antonio, Texas, 78215, United States Less <<
NCT05447663 Acute Myeloid Leukemia|Allogen... More >>eic Stem Cell Transplantation Less << PHASE1|PHASE2 TERMINATED 2023-10-26 Novartis Investigative Site, A... More >>ugsburg, 86179, Germany|Novartis Investigative Site, Freiburg, 79106, Germany|Novartis Investigative Site, Bergamo, BG, 24127, Italy|Novartis Investigative Site, Bologna, BO, 40138, Italy|Novartis Investigative Site, Sevilla, Andalucia, 41013, Spain|Novartis Investigative Site, Valencia, 46026, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.80mL

0.36mL

0.18mL

9.00mL

1.80mL

0.90mL

18.00mL

3.60mL

1.80mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories